<DOC>
	<DOCNO>NCT00330018</DOCNO>
	<brief_summary>The rationale protocol base need assess current post stem cell transplantation CMV prophylaxis strategy ( e.g . high-dose acyclovir plus pre-emptive treatment ) improve use valganciclovir . CMV common viral infection follow stem cell transplantation , cause significant morbidity mortality . Furthermore , CMV show associated number indirect effect SCT recipient include allograft dysfunction , acute chronic graft versus host disease ( GVHD ) . Valganciclovir show active oral ganciclovir , good intravenous ( i.v . ) ganciclovir treat newly diagnose CMV retinitis . The use valganciclovir CMV prophylaxis post stem cell transplantation never test control study . The investigator therefore suggest prospective , randomize study evaluate efficacy safety valganciclovir compare acyclovir prevention CMV disease allogeneic stem cell transplantation recipient .</brief_summary>
	<brief_title>Valganciclovir Prevention Cytomegalovirus ( CMV ) Reactivation Following Allogeneic-Stem Cell Transplantation ( SCT )</brief_title>
	<detailed_description>Cytomegalovirus ( CMV ) , common viral infection follow stem cell transplantation ( SCT ) , cause significant morbidity mortality . It result CMV pneumonitis , hepatitis , encephalitis gastrointestinal disease , well fever neutropenia . Furthermore , CMV show associated number indirect effect SCT recipient include reduced long-term patient survival , increase risk opportunistic infection , allograft dysfunction , acute chronic graft vs. host disease ( GVHD ) . SCT patient high risk seronegative donor , match unrelated donor , SCT T-cell depletion , patient cord blood SCT , patient GVHD . Valganciclovir , valine ester pro-drug ganciclovir , develop overcome limitation oral i.v . ganciclovir , single once-daily 900 mg oral dose provide comparable plasma ganciclovir exposure achieve 5 mg/kg i.v . ganciclovir . Its bioavailability 10-fold high oral ganciclovir ( ) . There already extensive clinical experience valganciclovir AIDS patient , prove effective i.v . ganciclovir treat newly diagnose CMV retinitis , patient solid organ transplant comparative data exist patient SCT . We therefore planned prospective , randomize study evaluate efficacy safety valganciclovir compare acyclovir prevention CMV disease SCT recipient .</detailed_description>
	<mesh_term>Acyclovir</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<criteria>1 . Undergoing allogeneic SCT match related unrelated donor without T cell depletion . 2 . Had acceptable engraftment . 3 . Can take oral medication within 10 day engraftment . 4 . Either recipient donor ( ) CMV seropositive . 1 . Not fulfil inclusion criterion . 2 . History CMV infection disease . 3 . AntiCMV therapy within past 15 day . 4 . Severe , uncontrolled diarrhea . 5 . Both recipient donor CMV seronegative . 6 . Evidence malabsorption . 7 . Inability comply study requirement . 8 . Known hypersensitivity contraindication ganciclovir valganciclovir . 9 . Pregnant lactating patient .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>BMT</keyword>
	<keyword>CMV</keyword>
	<keyword>GVHD</keyword>
</DOC>